193 related articles for article (PubMed ID: 23294321)
1. Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability.
Christiansen E; Due-Hansen ME; Urban C; Grundmann M; Schmidt J; Hansen SV; Hudson BD; Zaibi M; Markussen SB; Hagesaether E; Milligan G; Cawthorne MA; Kostenis E; Kassack MU; Ulven T
J Med Chem; 2013 Feb; 56(3):982-92. PubMed ID: 23294321
[TBL] [Abstract][Full Text] [Related]
2. Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves ADME properties.
Christiansen E; Due-Hansen ME; Urban C; Grundmann M; Schröder R; Hudson BD; Milligan G; Cawthorne MA; Kostenis E; Kassack MU; Ulven T
J Med Chem; 2012 Jul; 55(14):6624-8. PubMed ID: 22724451
[TBL] [Abstract][Full Text] [Related]
3. Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.
Christiansen E; Urban C; Grundmann M; Due-Hansen ME; Hagesaether E; Schmidt J; Pardo L; Ullrich S; Kostenis E; Kassack M; Ulven T
J Med Chem; 2011 Oct; 54(19):6691-703. PubMed ID: 21854074
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel orally bioavailable GPR40 agonists.
Lu H; Fei H; Yang F; Zheng S; Hu Q; Zhang L; Yuan J; Feng J; Sun P; Dong Q
Bioorg Med Chem Lett; 2013 May; 23(10):2920-4. PubMed ID: 23582779
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and structure-activity relationship studies of novel phenoxyacetamide-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
Li Z; Wang X; Xu X; Yang J; Qiu Q; Qiang H; Huang W; Qian H
Bioorg Med Chem; 2015 Oct; 23(20):6666-72. PubMed ID: 26420383
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists.
Sasaki S; Kitamura S; Negoro N; Suzuki M; Tsujihata Y; Suzuki N; Santou T; Kanzaki N; Harada M; Tanaka Y; Kobayashi M; Tada N; Funami M; Tanaka T; Yamamoto Y; Fukatsu K; Yasuma T; Momose Y
J Med Chem; 2011 Mar; 54(5):1365-78. PubMed ID: 21319751
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel pyrrole-based scaffold as potent and orally bioavailable free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
Li Z; Pan M; Su X; Dai Y; Fu M; Cai X; Shi W; Huang W; Qian H
Bioorg Med Chem; 2016 May; 24(9):1981-7. PubMed ID: 27020683
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel free fatty acid receptor 1 agonists bearing triazole core via click chemistry.
Li Z; Yang J; Wang X; Li H; Liu C; Wang N; Huang W; Qian H
Bioorg Med Chem; 2016 Nov; 24(21):5449-5454. PubMed ID: 27624524
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists.
Wang X; Zhao T; Yang B; Li Z; Cui J; Dai Y; Qiu Q; Qiang H; Huang W; Qian H
Bioorg Med Chem; 2015 Jan; 23(1):132-40. PubMed ID: 25481394
[TBL] [Abstract][Full Text] [Related]
10. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes.
Bharate SB; Nemmani KV; Vishwakarma RA
Expert Opin Ther Pat; 2009 Feb; 19(2):237-64. PubMed ID: 19441920
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists.
Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Toda N
Bioorg Med Chem Lett; 2014 Jul; 24(13):2949-53. PubMed ID: 24835985
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and Structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
Li Z; Qiu Q; Xu X; Wang X; Jiao L; Su X; Pan M; Huang W; Qian H
Eur J Med Chem; 2016 May; 113():246-57. PubMed ID: 26945112
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a Potent Free Fatty Acid 1 Receptor Agonist with Low Lipophilicity, Low Polar Surface Area, and Robust in Vivo Efficacy.
Hansen SV; Christiansen E; Urban C; Hudson BD; Stocker CJ; Due-Hansen ME; Wargent ET; Shimpukade B; Almeida R; Ejsing CS; Cawthorne MA; Kassack MU; Milligan G; Ulven T
J Med Chem; 2016 Mar; 59(6):2841-6. PubMed ID: 26928019
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes.
Xia Y; Chackalamannil S; Greenlee WJ; Jayne C; Neustadt B; Stamford A; Vaccaro H; Xu XL; Baker H; O'Neill K; Woods M; Hawes B; Kowalski T
Bioorg Med Chem Lett; 2011 Jun; 21(11):3290-6. PubMed ID: 21536438
[TBL] [Abstract][Full Text] [Related]
15. In vitro and mouse in vivo characterization of the potent free fatty acid 1 receptor agonist TUG-469.
Urban C; Hamacher A; Partke HJ; Roden M; Schinner S; Christiansen E; Due-Hansen ME; Ulven T; Gohlke H; Kassack MU
Naunyn Schmiedebergs Arch Pharmacol; 2013 Dec; 386(12):1021-30. PubMed ID: 23861168
[TBL] [Abstract][Full Text] [Related]
16. Discovery of phenylsulfonyl acetic acid derivatives with improved efficacy and safety as potent free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
Li Z; Liu C; Xu X; Qiu Q; Su X; Dai Y; Yang J; Li H; Shi W; Liao C; Pan M; Huang W; Qian H
Eur J Med Chem; 2017 Sep; 138():458-479. PubMed ID: 28689096
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists.
Shi J; Gu Z; Jurica EA; Wu X; Haque LE; Williams KN; Hernandez AS; Hong Z; Gao Q; Dabros M; Davulcu AH; Mathur A; Rampulla RA; Gupta AK; Jayaram R; Apedo A; Moore DB; Liu H; Kunselman LK; Brady EJ; Wilkes JJ; Zinker BA; Cai H; Shu YZ; Sun Q; Dierks EA; Foster KA; Xu C; Wang T; Panemangalore R; Cvijic ME; Xie C; Cao GG; Zhou M; Krupinski J; Whaley JM; Robl JA; Ewing WR; Ellsworth BA
J Med Chem; 2018 Feb; 61(3):681-694. PubMed ID: 29316397
[TBL] [Abstract][Full Text] [Related]
18. Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.
Phillips DP; Gao W; Yang Y; Zhang G; Lerario IK; Lau TL; Jiang J; Wang X; Nguyen DG; Bhat BG; Trotter C; Sullivan H; Welzel G; Landry J; Chen Y; Joseph SB; Li C; Gordon WP; Richmond W; Johnson K; Bretz A; Bursulaya B; Pan S; McNamara P; Seidel HM
J Med Chem; 2014 Apr; 57(8):3263-82. PubMed ID: 24666203
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological activity of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists.
Li Z; Wang X; Xu X; Yang J; Xia W; Zhou X; Huang W; Qian H
Bioorg Med Chem; 2015 Nov; 23(22):7158-64. PubMed ID: 26482570
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ.
Li Z; Zhou Z; Deng F; Li Y; Zhang D; Zhang L
Eur J Med Chem; 2018 Nov; 159():267-276. PubMed ID: 30296685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
